SCHEMBL2524094

SCHEMBL2524094

Cc1cccc(N2CCN(C(=O)[C@@H]3[C@@H](C(=O)O)CC4(CC4)CN3CC(C)(C)C)CC2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADAM10 O14672 8/20 0.51
▸ MMP2 P08253 7/20 0.51
▸ MMP9 P14780 5/20 0.51
▸ ERBB2 P04626 3/20 0.48
▸ FFAR4 Q5NUL3 1/20 0.43
▸ GPR119 Q8TDV5 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ MMP3 P08254 1/20 0.40
▸ NOTUM Q6P988 1/20 0.39
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4337187 0.86 ADAM10 (0.65) ADAM10MMP2MMP9ERBB2FFAR4
SCHEMBL2524097 0.77 ADAM10 (0.47) ADAM10MMP2MMP9ERBB2FFAR4
SCHEMBL2524093 0.77 ADAM10 (0.56) ADAM10MMP2MMP9ERBB2FFAR4
SCHEMBL1365268 0.76 ADAM10 (0.80) ADAM10MMP2MMP9ERBB2MMP3
SCHEMBL1364878 0.76 ADAM10 (0.80) ADAM10MMP2MMP9ERBB2MMP3
SCHEMBL3543143 0.72 ADAM10 (0.62) ADAM10MMP2MMP9ERBB2ALDH1A1
SCHEMBL1365270 0.72 ADAM10 (0.47) ADAM10MMP2MMP9ERBB2FFAR4
SCHEMBL1365658 0.69 ADAM10 (0.71) ADAM10MMP2MMP9ERBB2FFAR4
SCHEMBL1365026 0.69 ADAM10 (0.77) ADAM10MMP2MMP9ERBB2FFAR4
SCHEMBL1365025 0.69 ADAM10 (0.77) ADAM10MMP2MMP9ERBB2FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9403775-B2 AZA spiro alkane derivatives as inhibitors of metalloproteases INCYTE CORPORATION (US) 2016-08-02 — — US disclosed
US-20140187530-A1 AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases INCYTE CORPORATION (US) 2014-07-03 — — US disclosed
US-8039471-B2 Aza spiro alkane derivatives as inhibitors of metalloproteases INCYTE CORPORATION (US) 2011-10-18 — — US disclosed
US-7723349-B2 N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions INCYTE CORPORATION (US) 2010-05-25 — — US disclosed
US-20040259896-A1 N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions INCYTE CORPORATION 2004-12-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140187530-A1 AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases MMP9, MMP3, MMP12 ADAM10 29/4885MMP2 23/4885MMP9 1/4885
US-20040259896-A1 N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions MMP9, MMP25, HDAC5 ADAM10 258/4885MMP2 41/4885MMP9 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback